Skip to content

MDMA for addiction

Studies whose primary subject is both MDMA and Addiction, with an evidence synthesis read across the most-cited and most recent of them.

State of the evidence

Synthesized

Synthesized from 17 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for MDMA, ecstasy, molly, methylenedioxymethamphetamine, Addiction, substance use disorder, then ranked by relevance.

The research on MDMA for addiction is limited and mostly indirect. The only direct clinical evidence comes from small safety/tolerability studies in alcohol use disorder (4 and 20 participants), which found MDMA-assisted psychotherapy safe and tolerable but did not establish efficacy; a large randomized controlled trial in comorbid PTSD and alcohol use disorder is only at the protocol stage. Separately, several large surveys and pharmacovigilance analyses indicate MDMA itself carries dependence potential, so the evidence does not yet support a conclusion that MDMA treats addiction.

Evidence by study

Direction is which way each study's own result points, not our rating of the study. All 25 matching studies were reviewed; the 17 that directly address the question are shown here.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.
Study Design Sample size Direction Finding
First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder. 2021 clinical trial 20 Supports MDMA-assisted psychotherapy was reported as safe and tolerable in patients with alcohol use disorder.
First study of safety and tolerability of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: preliminary data on the first four participants. 2019 safety study 4 Supports MDMA-assisted psychotherapy was safe and tolerable in the first four participants with alcohol use disorder.
MDMA-assisted PTSD and Alcohol Therapy Trial (MPATHY): study protocol for a double-blind, randomised, controlled outpatient trial of MDMA-assisted integrated exposure-based therapy for comorbid post-traumatic stress disorder and alcohol use disorder 2026 randomized controlled trial 100 Unclear A double-blind trial is planned to test whether MDMA-assisted integrated exposure therapy improves PTSD and alcohol use outcomes versus active control-assisted therapy.
Why MDMA therapy for alcohol use disorder? And why now? 2018 theoretical or philosophical paper Supports Argues that MDMA-assisted psychotherapy may benefit patients with alcohol use disorder after medical detoxification because MDMA may help patients explore painful memories without being overwhelmed.
Psilocybin and MDMA in Couples Therapy: Investigating Treatment for Substance Use Disorders and Codependency 2025 narrative review Supports Proposes that combining psilocybin-assisted therapy for substance use disorders with MDMA for codependency in couples therapy may reduce addictive behaviors in one partner and codependent behaviors in the other.
Efficacy and Safety of Psychedelics in Mental Disorder Cases: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials 2025 umbrella review Mixed MDMA showed very large short-term effects for PTSD, but fewer meta-analyses were available for substance use disorder indications, and long-term safety data were lacking.
Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey 2020 cross-sectional survey Supports Psychedelic use was associated with self-reported reductions in problematic substance use, though causality cannot be determined from this design.
User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study 2010 cross-sectional survey 600 Supports Users reported benefits including help with addictions, while reporting less harm from classic hallucinogens than from MDMA, cannabis, ketamine, and alcohol.
Self-reported prevalence of dependence of MDMA compared to cocaine, mephedrone and ketamine among a sample of recreational poly-drug users 2014 cross-sectional survey Opposes MDMA users were more likely to report three or more DSM-IV dependence symptoms than users of cocaine, mephedrone, or ketamine, but less likely to desire to use less or seek help.
Test–re‐test reliability of DSM‐IV adopted criteria for 3,4‐methylenedioxymethamphetamine (MDMA) abuse and dependence: a cross‐national study 2009 test-retest study 593 Opposes 15% met MDMA abuse and 59% met MDMA dependence criteria, with moderate test-retest reliability and withdrawal symptoms supporting a separate diagnostic classification.
Ecstasy (MDMA) dependence 1999 case series 3 Opposes Three cases met criteria for MDMA dependence, and very heavy use may cause lasting neuronal changes; one case was linked to self-medication of PTSD.
Adverse events associated with classic psychedelics and MDMA: a real-world population-based study using the WHO pharmacovigilance database (VigiBase) 2025 pharmacovigilance database analysis Opposes MDMA reports were associated with significantly greater odds of alcohol abuse, substance use disorder, and substance dependence compared to acetaminophen and oxycodone controls.
Neural Correlates of the Severity of Cocaine, Heroin, Alcohol, MDMA and Cannabis Use in Polysubstance Abusers: A Resting-PET Brain Metabolism Study 2012 cross-sectional 49 Opposes Duration of MDMA use negatively correlated with brain metabolism in the dorsolateral prefrontal cortex and temporal cortex.
Potential Human Neurotoxicity of MDMA (‘Ecstasy’): Subjective Self-Reports, Evidence from an Italian Drug Addiction Centre and Clinical Case Studies 2000 review and clinical case series Opposes Longer-term, larger-dose MDMA consumers were found to be at high risk of developing psychopathological disturbances such as depression, psychotic disorders, and cognitive disturbances.
Methamphetamine and MDMA (Ecstasy) Neurotoxicity: 'of Mice and Men' 2004 review Opposes Evidence from rodent and primate studies suggests MDMA causes neurotoxicity in dopaminergic and serotonergic neurons.
Reinforcing Effects of MDMA (‘Ecstasy’) in Drug-Naive and Cocaine-Trained Rats 2001 experimental study Opposes MDMA was self-administered by rats, with reinforcing effects that did not differ between drug-naive and cocaine-trained animals.
Use and abuse of dissociative and psychedelic drugs in adolescence 2021 review Unclear Very little is known about MDMA effects in adolescents, though dissociatives and MDMA produce mixed reinforcing and aversive effects whose balance may differ between adolescents and adults.

Points of agreement

  • Small clinical studies in alcohol use disorder report MDMA-assisted psychotherapy is safe and tolerable, but they were not designed to test efficacy.
  • Multiple large surveys and pharmacovigilance data indicate MDMA carries dependence potential and is associated with substance-related harms.
  • Reviews and preclinical work describe neurotoxic and psychopathological risks with heavier or longer-term MDMA use.

Conflicts

  • Some surveys and theoretical papers suggest psychedelics including MDMA may reduce problematic substance use, while pharmacovigilance and dependence surveys associate MDMA with substance use disorder and dependence.
  • MDMA is described as having low dependence potential in some clinical contexts, yet survey and case data show a substantial proportion of users meeting dependence criteria.

Gaps

  • No completed randomized controlled trial has tested MDMA-assisted therapy for addiction outcomes; the only large trial is at the protocol stage.
  • Efficacy data for MDMA in alcohol use disorder are absent; existing clinical studies addressed safety and tolerability only.
  • Long-term durability of any benefit, blinding integrity, optimal dose, and effects in adolescents and non-alcohol substance use disorders remain unstudied.
Browse these studies in the library

Common questions

What does the research agree on about MDMA for addiction?
  • Small clinical studies in alcohol use disorder report MDMA-assisted psychotherapy is safe and tolerable, but they were not designed to test efficacy.
  • Multiple large surveys and pharmacovigilance data indicate MDMA carries dependence potential and is associated with substance-related harms.
  • Reviews and preclinical work describe neurotoxic and psychopathological risks with heavier or longer-term MDMA use.
Where do studies on MDMA for addiction conflict?
  • Some surveys and theoretical papers suggest psychedelics including MDMA may reduce problematic substance use, while pharmacovigilance and dependence surveys associate MDMA with substance use disorder and dependence.
  • MDMA is described as having low dependence potential in some clinical contexts, yet survey and case data show a substantial proportion of users meeting dependence criteria.
What is still unknown about MDMA for addiction?
  • No completed randomized controlled trial has tested MDMA-assisted therapy for addiction outcomes; the only large trial is at the protocol stage.
  • Efficacy data for MDMA in alcohol use disorder are absent; existing clinical studies addressed safety and tolerability only.
  • Long-term durability of any benefit, blinding integrity, optimal dose, and effects in adolescents and non-alcohol substance use disorders remain unstudied.
How we analyze this

This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is MDMA for addiction, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.

A study qualifies only when MDMA for addiction or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.

The full method, including what a person does and does not review, is on the methods page.

Ask your own question in the Research Synthesis Tool

76 articles · 20 from the last two years · 146,324 participants across 26 studies reporting sample size

Common study designs

review 21 observational cohort 6 cross-sectional study 5 cross-sectional survey 4 theoretical or philosophical paper 4

Research volume by year

Compare topics →

71 studies whose primary subject is MDMA for addiction since 2003

Studies about MDMA for addiction per year, 2003 to 2026, peaking at 9 in 2024 Bar chart: one bar per year, taller where more studies were published that year. 0 5 10 2005 2010 2015 2020 2025
2026 is partial
Show the numbers
Studies about MDMA for addiction per year, 2003 to 2026, peaking at 9 in 2024
Year Studies
2003 1
2004 1
2005 1
2006 1
2007 0
2008 1
2009 2
2010 3
2011 0
2012 3
2013 1
2014 2
2015 1
2016 1
2017 2
2018 2
2019 2
2020 5
2021 6
2022 4
2023 7
2024 9
2025 9
2026 7

Research

Synthesize the evidence →

MDMA-assisted PTSD and Alcohol Therapy Trial (MPATHY): study protocol for a double-blind, randomised, controlled outpatient trial of MDMA-assisted integrated exposure-based therapy for comorbid post-traumatic stress disorder and alcohol use disorder

BMJ Open July 1, 2026 Kirsten Morley, Shalini Arunogiri, Katherine L. Mills et al.

INTRODUCTION: The treatment of comorbid post-traumatic stress disorder (PTSD) and alcohol use disorder (AUD) is significantly more challenging than the treatment of either disorder alone. While gold standard evidence-based treatments exist for this comorbidity, clinically significant improvements are only observed in approximately half of clinical trial participants. The use of adjunctive...

DOI: 10.1136/bmjopen-2025-114896 (opens in new tab) Full text (opens in new tab) Alcohol use disorder Major depressive disorder Dosing Randomized controlled trial +11

Happy water overdose: A trending but fatal street drug

Myanmar Medical Journal June 4, 2026 Aung Kyaw Thu, Zaw Hlaing Toe, Si Thu Linn

“Happy water” has been gaining popularity among party goers. The effect of consuming this drug can be fatal. Two patients of “Happy water” overdose were admitted for reduced level of consciousness after enjoying a farewell party at nightclub. Urine for toxicology screening was found to be positive for methylenedioxymethamphetamine (MDMA), methamphetamine, diazepam and tramadol. “Happy water” is...

DOI: 10.64455/xmma0028 (opens in new tab) MDMA Addiction Mephedrone Stimulant +13

Synthetic Drugs and Behavioural Addictions: LSD, MDMA and Digital Toxicity

June 1, 2026 Sharda More-Pol

The emergence of contemporary psychological stressors, synthetic psychoactive substance abuse, and non-substance behavioral dependency networks presents critical investigative challenges within public healthcare and classical toxicology (Agadatantra), traditionally analyzed through the concepts of Madya (intoxicants), Mada (intoxication), and severe cognitive perversion (Prajñāparādha). This...

DOI: 10.63247/ayurveda360.cfa.agadatantra.c011 (opens in new tab) Lysergic acid diethylamide MDMA Cognition Parallels +5

The Ecstasy of Gold in Neurodiversity: Focus on the Use of Psychedelics in Autism Spectrum Disorder

Preprints.org April 29, 2026 Stefano Marini, Domenico de Berardis preprint

Psychedelic drugs are serotonergic hallucinogens that can be divided into two types: naturally occurring (psilocybin, psilocin, and N,N-dimethyltryptamine) and synthetic (LSD, MDMA, 2,5-dimethoxy-4-iodoamphetamine, and ketamine). Psychedelics generally work on 5-hydroxytryptamine receptors and might be useful in cognitive enhancement, brain connectivity, neuroplasticity, and neuronal...

DOI: 10.20944/preprints202604.1998.v1 (opens in new tab) Addiction Autism spectrum disorder Hallucinogen Psychopathology +4

New psychoactive substances (designer drugs): an approach to classification

Neurology Bulletin March 23, 2026 Azat R. Asadullin, Elvina A. Akhmetova, Ilia S. Efremov et al.

BACKGROUND: Substance use disorders remain a global public health problem. In recent decades, the drug market has undergone substantial changes, with traditional drugs increasingly replaced by new psychoactive substances characterized by high toxicity and strong addictive potential. Their distribution via the Internet and social media impedes control and increases risks to public health. AIM:...

DOI: 10.17816/nb689708 (opens in new tab) Addiction Lysergic acid diethylamide MDMA Psilocybin +10

Partydrogen im Überblick

Psychopharmakotherapie 2026 Antonia Bendau, Felix Betzler, Twyla Michnevich et al. 1 citation

Party drugs encompass a broad spectrum of legal and illegal psychoactive substances used in party settings such as clubs, festivals, raves or private gatherings to modulate mood, perception, social interaction and bodily states. Most commonly, alcohol and cannabis are consumed, followed by amphetamine, MDMA (“ecstasy”), cocaine and ketamine. Synthetic cathinones, GHB/GBL (“liquid ecstasy”),...

DOI: 10.52778/ppt20260001 (opens in new tab) Serotonergic MDMA Addiction Cannabis +16

Possible Effects of MDMA on Vehicle Driving Competencies

Transportation research procedia 2026 Samuel Hubočan, Matúš Madleňák

Safety and security in traffic is a fundamental need of every road user. There are many factors that have a direct impact on this need. It can be assumed that vehicle driving competencies represent one of these factors. A vehicle driver should be vigilant, decisive and capable of practical use of traffic rules implied by the legal system. Addictive substances can disrupt driver’s capabilities...

DOI: 10.1016/j.trpro.2025.12.042 (opens in new tab) MDMA Addiction Poison control Orientation vector space +3

Efficacy and Safety of Psychedelics in Mental Disorder Cases: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials

Journal of Clinical Medicine December 29, 2025 Monika Dominiak, Adam Gędek, Szymon Modrzejewski et al. 2 citations

Background: Psychedelic-assisted therapy is gaining renewed attention as a potential treatment for various mental disorders. Despite increasing numbers of randomized controlled trials (RCTs) and meta-analyses, a comprehensive synthesis of the evidence across different substances and indications is lacking. This umbrella review aims to evaluate the effectiveness and safety of...

DOI: 10.3390/jcm15010253 (opens in new tab) MDMA Psilocybin Major depressive disorder Alcohol use disorder +8

Adverse events associated with classic psychedelics and MDMA: a real-world population-based study using the WHO pharmacovigilance database (VigiBase)

Psychiatry Research December 29, 2025 Omer A. Syed, Sean M. Nestor, Muhammad Ishrat Husain et al. 1 citation

Psychedelic use has greatly increased within clinical and recreational settings over recent years. While demonstrating a favorable safety profile within certain clinical populations, little empirical research has explored safety of psychedelic use within real-world samples. Using the World Health Organization (WHO) VigiBase, a comprehensive global pharmacovigilance database with voluntary...

DOI: 10.1016/j.psychres.2025.116929 (opens in new tab) Psilocybin MDMA Mescaline Ecstasy +13

Psilocybin and MDMA in Couples Therapy: Investigating Treatment for Substance Use Disorders and Codependency

Contemporary Family Therapy December 11, 2025 Samuel Hosford, Heather Austin-Robillard

Abstract Substance use disorders (SUDs) are increasingly common in the United States, and while this may be a dilemma for those using, it also inflicts problems for those around the user. In couples where drug abuse is present, negative codependent characteristics can arise independently in the non-user, having a damaging effect on the couple dynamic. This is a narrative review to identify how...

DOI: 10.1007/s10591-025-09766-8 (opens in new tab) Full text (opens in new tab) MDMA Psilocybin Addiction Spouse +7

Clinical trials

All mdma for addiction trials →